Tazeen Ahmad
Stock Analyst at B of A Securities
(3.35)
# 1,023
Out of 5,182 analysts
224
Total ratings
48.19%
Success rate
2.98%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $262 → $292 | $231.05 | +26.38% | 13 | Apr 16, 2026 | |
| BCAX Bicara Therapeutics | Initiates: Buy | $35 | $23.63 | +48.12% | 1 | Mar 25, 2026 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $29 | $22.24 | +30.40% | 17 | Mar 25, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $139 → $149 | $85.18 | +74.93% | 11 | Mar 20, 2026 | |
| PTCT PTC Therapeutics | Maintains: Buy | $97 → $93 | $70.85 | +31.26% | 20 | Feb 20, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $529 → $462 | $310.58 | +48.75% | 7 | Jan 30, 2026 | |
| BLTE Belite Bio | Initiates: Buy | $195 | $167.42 | +16.47% | 1 | Jan 26, 2026 | |
| APLS Apellis Pharmaceuticals | Upgrades: Buy | $28 | $40.89 | -31.52% | 10 | Jan 21, 2026 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Buy | $627 → $860 | $746.58 | +15.19% | 1 | Jan 7, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $72 → $58 | $24.61 | +135.68% | 7 | Jan 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $6 → $7 | $7.75 | -9.68% | 7 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $112 | $88.77 | +26.17% | 1 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $30 | $30.04 | -0.13% | 5 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $53 | $47.33 | +11.98% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $104 | $96.74 | +7.50% | 6 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $880 → $887 | $793.22 | +11.82% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $16 | $20.64 | -22.48% | 26 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $134 | $108.60 | +23.39% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $6.72 | +19.05% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $9.01 | +66.48% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $10.72 | -62.69% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $35.53 | -77.48% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $20.25 | +33.33% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $10.63 | +163.41% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $9.80 | +308.16% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $131.18 | +36.45% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $19.56 | +12.47% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.66 | +80.72% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.46 | +3.73% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $6.26 | +59.74% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.37 | +337.96% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $9.66 | +55.28% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $4.09 | -51.10% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $4.31 | +39.21% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $33.03 | -54.59% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $337.29 | -82.21% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.88 | +751.06% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $140.60 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $19.76 | +1,418.22% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.86 | +214.69% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $24.88 | +92.93% | 6 | Oct 10, 2018 |
Ascendis Pharma
Apr 16, 2026
Maintains: Buy
Price Target: $262 → $292
Current: $231.05
Upside: +26.38%
Bicara Therapeutics
Mar 25, 2026
Initiates: Buy
Price Target: $35
Current: $23.63
Upside: +48.12%
ACADIA Pharmaceuticals
Mar 25, 2026
Upgrades: Buy
Price Target: $29
Current: $22.24
Upside: +30.40%
Rhythm Pharmaceuticals
Mar 20, 2026
Maintains: Buy
Price Target: $139 → $149
Current: $85.18
Upside: +74.93%
PTC Therapeutics
Feb 20, 2026
Maintains: Buy
Price Target: $97 → $93
Current: $70.85
Upside: +31.26%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Buy
Price Target: $529 → $462
Current: $310.58
Upside: +48.75%
Belite Bio
Jan 26, 2026
Initiates: Buy
Price Target: $195
Current: $167.42
Upside: +16.47%
Apellis Pharmaceuticals
Jan 21, 2026
Upgrades: Buy
Price Target: $28
Current: $40.89
Upside: -31.52%
Regeneron Pharmaceuticals
Jan 7, 2026
Upgrades: Buy
Price Target: $627 → $860
Current: $746.58
Upside: +15.19%
Ultragenyx Pharmaceutical
Jan 2, 2026
Maintains: Buy
Price Target: $72 → $58
Current: $24.61
Upside: +135.68%
Dec 9, 2025
Maintains: Underperform
Price Target: $6 → $7
Current: $7.75
Upside: -9.68%
Dec 9, 2025
Maintains: Buy
Price Target: $71 → $112
Current: $88.77
Upside: +26.17%
Dec 4, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $30.04
Upside: -0.13%
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $47.33
Upside: +11.98%
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $96.74
Upside: +7.50%
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $793.22
Upside: +11.82%
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $20.64
Upside: -22.48%
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $108.60
Upside: +23.39%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $6.72
Upside: +19.05%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $9.01
Upside: +66.48%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $10.72
Upside: -62.69%
May 19, 2025
Maintains: Underperform
Price Target: $10 → $8
Current: $35.53
Upside: -77.48%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $20.25
Upside: +33.33%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $10.63
Upside: +163.41%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $9.80
Upside: +308.16%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $131.18
Upside: +36.45%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $19.56
Upside: +12.47%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.66
Upside: +80.72%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.46
Upside: +3.73%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $6.26
Upside: +59.74%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.37
Upside: +337.96%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $9.66
Upside: +55.28%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $4.09
Upside: -51.10%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $4.31
Upside: +39.21%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $33.03
Upside: -54.59%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $337.29
Upside: -82.21%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.88
Upside: +751.06%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $140.60
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $19.76
Upside: +1,418.22%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.86
Upside: +214.69%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $24.88
Upside: +92.93%